Primidone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Primidone: From Epilepsy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Primidone is a broad-spectrum antiepileptic agent, metabolised to phenobarbital and PEMA, though confirmed UK licensing/indication data are not currently available for this drug in this evidence pack. The TxGNN model predicts a possible link to Trigeminal Nerve Neoplasm with a 99.99% prediction score, but zero clinical trials and zero relevant publications currently support this specific indication — the model’s own rationale flags this as a likely knowledge-graph artefact rather than a genuine pharmacological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy / seizure disorders (inferred from the drug’s pharmacological classification in the evidence pack; no confirmed UK licensing text available) |
| Predicted New Indication | Trigeminal Nerve Neoplasm |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, formally-sourced mechanism of action data for Primidone is currently a data gap (flagged as a blocking issue in this pack). Based on the mechanistic notes attached to this prediction, Primidone is metabolised to phenobarbital and phenylethylmalonamide (PEMA), acting on GABA-A receptors and voltage-gated sodium channels — the pharmacology of a classic broad-spectrum antiepileptic drug.
There is no known mechanistic connection between this GABA-A/sodium-channel activity and the tumour proliferation pathways implicated in trigeminal nerve neoplasms (e.g. schwannoma). The evidence pack itself notes that the very high TxGNN score most likely reflects lexical/embedding proximity within the knowledge graph — the model may be conflating “trigeminal” as it appears in trigeminal neuralgia (a pain condition antiepileptics are sometimes used for) with trigeminal nerve neoplasm (a structural tumour), rather than identifying a true pharmacological relationship.
Given the complete absence of supporting clinical trials or literature, and the explicit internal caveat about graph-based confusion, this specific prediction should be treated as low-confidence and not pursued as a repurposing hypothesis without independent mechanistic or preclinical validation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Trigeminal Nerve Neoplasm) has no supporting clinical trials or literature (Evidence Level L5), and the accompanying rationale explicitly identifies this as a probable knowledge-graph artefact rather than a genuine pharmacological signal. Primidone is also not currently marketed in the UK, and core drug-level data — labelling warnings/contraindications and confirmed mechanism of action — are outstanding data gaps (one of them blocking).
To proceed, the following is needed:
- TFDA/MHRA product labelling (warnings, contraindications) — currently a blocking data gap preventing any safety pre-assessment
- Confirmed mechanism of action data from DrugBank or an SmPC
- Independent preclinical or mechanistic evidence specifically linking Primidone to trigeminal nerve tumour biology, given the current complete absence of supporting data
- If repurposing work on Primidone continues, consider redirecting attention to the reflex-epilepsy candidates elsewhere in this evidence pack (e.g. audiogenic seizures, startle epilepsy, eating seizures, trigeminal neuralgia), which carry stronger literature support (L3–L4) — though these too currently lack dedicated clinical trials and would need a “Research Question” stage workup before any Go decision
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.